Microbiome in Hidradenitis Suppurativa: Current Evidence and Practice
Recommended Citation
Hwang J, Rick J, Hsiao J, Hamzavi IH, and Shi VY. Microbiome in Hidradenitis Suppurativa: Current Evidence and Practice. Curr Dermatol Rep 2022; 11(1):21-39
Document Type
Article
Publication Date
3-11-2022
Publication Title
Current Dermatology Reports
Abstract
The role of the host microbiome in hidradenitis suppurativa (HS) is heavily debated. Previous culture-based methods have not led to strong conclusions. Despite antibiotics being a mainstay of HS treatment, microbiome research in other cutaneous inflammatory diseases such as atopic dermatitis and psoriasis is more robust. This review evaluates the current evidence regarding the influence of skin and gut dysbiosis on HS pathogenesis. Current and potential future microbiome modulating therapeutic modalities are also discussed. Recent Findings: Newer studies using 16S genome sequencing have furthered our understanding of the human microbiome. We find promising evidence for cutaneous dysbiosis but limited evidence for gut dysbiosis. Summary: Both areas need future studies focusing on the temporal relationship between the microbiome and disease flare and remission and the impact of treatments on the microbiome. Detailed knowledge of microbial shifts will lead to innovations in diagnosis and treatment in the era of precision medicine.
Volume
11
Issue
1
First Page
21
Last Page
39